Les meilleurs doctors en Turquie pour votre Biopsie mammaire - TOP 54 des médecins

2023 – Hôpital d'enseignement et de recherche Gaziosmanpaşa Taksim d'Istanbul – Clinique de chirurgie générale Professeur associé

2013 – Hôpital d'enseignement et de recherche Gaziosmanpaşa Taksim d'Istanbul – Spécialiste en chirurgie générale

2008 – 2013 Hôpital privé médical Park Fatih, spécialiste en chirurgie générale – médecin-chef adjoint

2005 – 2007 Hôpital privé Gelişim – Spécialiste en chirurgie générale

2003 – 2005 Hôpital privé Şafak d'Istanbul – Spécialiste en chirurgie générale – Médecin-chef

2002 – 2003 HÔPITAL D’ÉDUCATION ET DE RECHERCHE HASEKİ D’ISTANBUL – Médecin assistant en chirurgie générale

1998 – 2002 Hôpital d’enseignement et de recherche d’Ankara – Médecin assistant en chirurgie générale

1998 – Université des Sciences de la Santé – Centre d’Application et de Recherche en Santé Haseki d’Istanbul – Spécialisation Médicale

1991 – Faculté de médecine de l’Université de Gazi – Licence

Certificats

Atelier de diagnostic et de traitement de l'IGM, mammite granulomateuse, Kocaeli, certificat, 07.10.2023 (national)

ibreast 51 – Reconstruction par lambeau gratuit, chirurgie du cancer du sein, en ligne, certificat, 30.09.2023 – 30.09.2023 (international)

ibreast 50- Cancer du sein triple négatif, Cancer du sein, En ligne, Certificat, 02.09.2023 -02.09.2023 (International)

ibreast 49 - Reconstruction par implants, cancer du sein, en ligne, certificat, 12.08.2023 -12.08.2023 (international)

ibreast 48- DCIS, İbreast 48- DCIS, en ligne, certificat, 15.07.2023 -15.07.2023 (international)

ibreast 47 - Actualisations de la conférence, Cancer du sein, En ligne, Certificat, 25.06.2023 -25.06.2023 (International)

ibreast 46- Margin Revisited, Cancer du sein, En ligne, Certificat, 10.06.2023 -10.06.2023 (International)

1. International 4. Congrès national de chirurgie mammaire, chirurgie mammaire, Ürgüp, Certificat, 05.05.2023 – 07.05.2023 (International)

ibreast 44- Maladie HER2 positive, Cancer du sein, En ligne, Certificat, 29.04.2023 -29.04.2023 (International)

St-Gallen 2023, Réunion de synthèse du congrès de St-Gall, Istanbul, Certificat, 01.04.2023 -01.04.2023 (National)

ibreast 43- Save The Nipple, Cancer du sein, En ligne, Certificat, 25.03.2023 -25.03.2023 (International)

ibreast 42-Chest Wall Perforator Flap Revisited, Cancer du sein, En ligne, Certificat, 25.02.2023 -25.02.2023 (International)

ibreast 41- Lésions à haut risque et B3, maladies du sein, en ligne, certificat, 28.01.2023 -28.01.2023 (international)

15. Réunion sur les nouvelles approches en matière d'éducation sur le cancer du sein, cancer du sein, Istanbul, certificat, 07.01.2023 – 08.01.2023 (national)

Articles qu'elle a écrits et auxquels elle a participé ;

1.YILDIRIM EMİNE, BEKTAŞ SİBEL, YETİŞ FIRAT, YILDIZ EREN OZAN, ÖZDEMİR MUHAMMED, KOMUT NESLİHAN, ÇALIK MUSTAFA, ER AHMET MUZAFFER. Corrélation entre la réponse complète pathologique mammaire et axillaire après chimiothérapie néoadjuvante dans le cancer du sein. Annali Italiani di Chirurgia, 2023

2.UZUN NEDIM, YILDIRIM EMİNE. Relation entre le type de toilettes et les hémorroïdes. Université Bezmialem Vakif, 2022

3.YILDIZ EREN OZAN, YILDIRIM EMİNE, ORHUN ERDOĞAN KIVILCIM, ERYILMAZ İKLİL, YÜNLÜEL EMİR MEHMET, YETİŞ FIRAT, ULUKENT SUAT CAN. L'effet de la pandémie de covid 19 sur le nombre de patients traités pour appendicite aiguë aiguë et complexe. Annali Italiani de Chirurgie, 2202

4.YILDIRIM EMİNE, BEKTAŞ SİBEL, ÖZDEMİR MUHAMMED, KARAGÜLLE AHENK, ER AHMET MUZAFFER, UÇAR NEŞE. Taux d'amélioration du CCIS, du papillome intra-canalaire et des autres lésions mammaires à haut risque. Journal médical Hamidiye, 2022

5.ÖZKAN GÜMÜŞKAYA PERİHAN, ALTUN ÖZGÜR, KARAKÜTÜK YÜZTAŞ NUR, ÖZSOY NESLİHAN, AYDIN TUTAK GÜLTEN, YILDIRIM EMİNE, ADAŞ MİNE, KÜÇÜK MEHMET. COVID-19 Pnömonisi Sonrası AntiHBs Değerlerindeki Değişiklikler. Journal de médecine contemporaine, 2022;12(4),

6.KOMUT NESLİHAN, BEKTAŞ SİBEL, YILDIRIM EMİNE. Relation entre le bourgeonnement tumoral et l'expression de GOLPH3 et les paramètres pronostiques histopathologiques dans l'adénocarcinome colorectal. Annales de pathologie diagnostique 2022 juin ;58 :151933.

7.KAYADİBİ YASEMİN, UÇAR NEŞE, AKAN YEŞİM NAMDAR, KAYA MEHMET FATİH, YILDIRIM EMİNE, ALADAĞ KURT SEDA, SOYLU BOY FATMA NUR, TAŞKIN FÜSUN, İÇTEN GÜL ESEN. Résultats d'imagerie par résonance magnétique associés à une récidive de la mammite granulomateuse idiopathique. Imagerie clinique, 2022

8. YILDIRIM EMİNE, KEĞİN MURAT, ÖZDEMİR MUHAMMED, BEKTAŞ SİBEL, PELEN ZEKERİYA, ER AHMET MUZAFFER. Tumeurs de l'Appendice ; Résultats d’une seule institution et d’expériences décennales. Journal turc de traumatologie et de chirurgie d'urgence, 2022 ; 28(3), 352-360

9.YILDIRIM EMİNE, YILDIZ EREN OZAN, ERYILMAZ İKLİL, ER AHMET MUZAFFER, BEKTAŞ SİBEL. Comparaison du volume mammaire excisé, du taux de réexcision et de la positivité des marges lors de la chirurgie conservatrice du sein chez les patientes atteintes d'un cancer du sein utilisant et n'utilisant pas de chimiothérapie néoadjuvante. Journal of Surgery in Medicine, 2022 ; 6

10.YILDIRIM EMİNE, BEKTAŞ SİBEL, PELEN ZEKERİYA, YANIK İREM, ER AHMET MUZAFFER, ÇENGEL FERHAT, ÖZKAN GÜMÜŞKAYA PERİHAN. Facteurs histopathologiques, radiologiques et démographiques prédisant la réponse au traitement néoadjuvant du cancer rectal. Journal du cancer gastro-intestinal, 2022 ;53(1)

11.KAYADİBİ YASEMİN, KOÇAK BURAK, UÇAR NEŞE, AKAN YEŞİM NAMDAR, YILDIRIM EMİNE, BEKTAŞ SİBEL. Radiomique IRM du cancer du sein : prédiction basée sur l'apprentissage automatique de l'état d'invasion lymphovasculaire. Radiologie académique, 2022 ; 29(1), 126-134.

12.YILDIRIM EMİNE, UÇAR NEŞE, YETİŞ FIRAT, KAYADİBİ YASEMİN, BEKTAŞ SİBEL. Performances diagnostiques de l'imagerie mammaire avec échographie, résonance magnétique et mammographie dans l'évaluation de la tumeur résiduelle après chimiothérapie néoadjuvante chez les patientes atteintes d'un cancer du sein. Journal of Surgery and Medicine, 2022;6(1), 43-48

13.YILDIRIM EMİNE, BEKTAŞ SİBEL, GÖKTAŞ AYDIN SABİN, ER AHMET MUZAFFER, YANIK İREM, ÖZKAN GÜMÜŞKAYA PERİHAN, YILMAZ BARBAROS UTKU, BİLİCİ AHMET, ÖNCEL MUSTAFA. Facteurs prédisant la réponse à la chimiothérapie néoadjuvante dans le cancer gastrique localement avancé. Journal de la Faculté de médecine d'Istanbul / Istanbul Tıp Fakültesi Dergisi, 2022 ;85(1), 41-50.

14.YILDIRIM EMİNE, Pelen Zekeriya, KEĞİN MURAT, UÇAR NEŞE, KAYADİBİ YASEMİN, GÜNDOĞAR ÖZGECAN. Évaluation de la fiabilité de l'échographie préopératoire et de la biopsie par aspiration à l'aiguille fine guidée par échographie dans la stadification axillaire chez les patientes atteintes d'un cancer du sein. Journal of Academic Research in Medicine, 2021;11(3), 269-276.,

15. KAYADİBİ YASEMİN, UÇAR NEŞE, KAYA MEHMET FATİH, YILDIRIM EMİNE, BEKTAŞ SİBEL. Caractérisation des microcalcifications suspectes en mammographie par élastographie à ondes de cisaillement 2D. Échographie en médecine et biologie, 2022 ; 47(9), 2532-2542.

16.KAYADİBİ YASEMİN, TEKCAN ŞANLI DENİZ ESİN, UÇAR NEŞE, YILDIRIM EMİNE, ŞANLI AHMET NECATİ. Évaluation des caractéristiques d'apparence des microcalcifications suspectes détectées par échographie. Journal de recherche universitaire en médecine, 2022 ; 11(2), 199-205.

17.YILDIRIM EMİNE, ÖZER HİLAL, ÖZER İLTER, KOYUNCU ADIL, YILDIRIM TİMUR. Les effets sur la translocation bactérienne et les dommages tissulaires du traitement au sélénium dans un modèle expérimental d'ischémie-reperfusion intestinale. Journal turc de traumatologie et de chirurgie d'urgence, 2021 ;27(4), 389-394.

18.YILDIRIM EMİNE, AKBAŞ PELİN, ORHUN ERDOĞAN KIVILCIM, BEKTAŞ SİBEL, ÖZKAN GÜMÜŞKAYA PERİHAN, ER AHMET MUZAFFER, PALTURA CEKİ. La comparaison des résultats histopathologiques des biopsies thyroïdiennes par aspiration à l'aiguille fine chez les 795 patients ayant subi une thyroïdectomie. Cytopathologie diagnostique, 2021

Endocrinologist

Prof. Dr. Sezer Sağlam is a medical oncologist at Gayrettepe Florence Nightingale Hospital. He specializes in gastrointestinal and breast cancers. He has contributed to cancer care through research, especially with his study on the best timing for surgery after neoadjuvant therapy in rectal cancer. This work has influenced global treatment protocols.

Dr. Sağlam has led clinical trials in targeted therapies and precision medicine. His research on liver-transplanted patients with hepatocellular carcinoma was nominated for the 2024 International Best Researcher Award. He is a member of ASCO, ESMO, and ENET. Dr. Sağlam provides personalized and evidence-based oncology care.

Professeur d'oncochirurgie et de proctologie

Éducation:

Cours pédagogique sur « Cartographie lymphatique et ganglion sentinelle »

Juin 1998, MDA Cancer Center, Houston, Texas, États-Unis

Chirurgie générale

Février 1993 – décembre 1996, Hôpital Şişli Etfal, Istanbul, Turquie

Chirurgie générale

Mai 1990 – janvier 1993, CHU de Lille, Lille, France

MARYLAND

1983 – 1990, École de médecine Cerrahpasa, Istanbul, Turquie

Expérience

Chirurgien général traitant, janvier 1998 – aujourd’hui

Hôpital métropolitain FN, Istanbul, Turquie

Centre américain du cancer, chirurgie mammaire

Chirurgien général traitant, 1996 – aujourd’hui

Centre de diagnostic Medmar, Istanbul, Turquie

Diagnostic et surveillance avec des techniques sophistiquées

Chirurgien général, 1996 – 1998

Centre médical Guzelbahce et hôpital Yeditepe, Istanbul, Turquie

Spécialisée en chirurgie du sein et de la thyroïde

Éducation et spécialisation

• 2006 : Faculté de médecine de l'Université de Kocaeli
• 2014 : Faculté de médecine de l'Université d'Akdeniz, Médecine interne
• 2018 : Faculté de médecine de l'Université d'Akdeniz, Oncologie médicale

Expérience

• 2006 - 2008 : Hôpital du district de Konya Derebucak
• 2009 - 2015 : Hôpital universitaire d'Akdeniz
• 2015 : Hôpital d'État d'Antalya Kaş
• 2015 - 2016 : Faculté de médecine de l'Université d'İnönü
• 2016 - 2021 : Hôpital universitaire d'Akdeniz
• 2021 - 2023 : Hôpital de formation et de recherche d'Antalya

Dr. Saban Sec is a medical oncologist with experience at leading hospitals, including Haseki Training and Research Hospital, Prof. Dr. Cemil Taşcıoğlu City Hospital, and Bahçelievler Medikalpark Hospital. He currently represents specialist physicians in the Turkish Medical Oncology Association. He is also a member of the Istanbul Medical Chamber and the Turkish Medical Oncology Association.

Dr. Sec treats breast, lung, gastrointestinal, prostate, urogenital, head and neck cancers, as well as sarcomas and rare tumors. He has published many peer-reviewed articles on cancer prognosis, treatment outcomes, and survival rates. His research includes studies with large patient groups, such as 138 patients with HER2-positive metastatic gastric cancer. Dr. Sec focuses on prognostic factors and treatment responses in different cancers. He is dedicated to improving cancer care.

Areas of Interests

• Genital Laser Application ( Vajinal  Rejuvenation , Laser Incontinence Treatment)
• Aesthetic  Genital  Surgery ( Labioplastia, Vaginoplastia, Perineoplastia )
• Vaginismus Treatment.
• Treatment Of Female Sexual Function Disorders.
• Hormonal & Non-Hormonal Treatment.
• Laser Incontinence Treatment.
• Medical Treatment İn Incontinence.

Education

• Hacettepe  University  Faculty of  Medicine, ANKARA.
• SBÜ. ANKARA Dr. Zekai Tahir Burak  Training and  Research  Hospital.

Experience

• SBÜ.ANKARA Dr. Zekai Tahir Burak Training and Research Hospital.
• Antalya Training and  Research  Hospital,
• Jinefem , Private Gynecology Center, ANTALYA
• SM Clinic, Private Gynecology Center, ANTALYA
• Liv Hospital Ulus, İSTANBUL

Research:

• Gestational  Diabetic  Evaluation of  Affinity in Pregnant  Woman in Turkey.
• The  Effect of Intrauterin Insemination on  Pregnancy  Rates in Infertile Woman in 456 cycles.
• The  Effect of  Genital  Laser  Applications on  Urinary  Incontinence  Treatment.
• The  Effect of  Genital  Laser  Applications  on  Vaginal  Atrofi  in  Menopause.
• Distribution of Human Papilloma Virus (HPV) İnfection in the Mediterranean Region in Turkey.

Areas of Interests

• Pregnancy follow-up and birth
• Vaginal Infections and Sexually Transmitted Diseases
• Women's Cancer Screening and Cervical Cancer Vaccination
• Menopause Follow-up
• Family Planning (Spiral, implant, etc.)
• Recurrent pregnancy losses and miscarriages
• Polycystic ovary syndrome
• Diagnosis and treatment of infertility
• Vaccination
• Genital Warts and Treatment
• Diagnosis and Treatment of Urinary Incontinence
• Hysteroscopic surgery and Laparoscopic surgery (Closed method)
• Myoma Surgeries
• Ovarian Cysts
• Genital aesthetics (labioplasty, vaginoplasty, tightening, sagging operations)

Education

• Tepecik Training and Research Hospital
• Istanbul Faculty of Medicine
• Heidelberg University - Infertility and Reproductive Medicine Clinic
• Agaplesion General Hospital Hagen - Gynecology Clinic
• Poland Poznan Medical Faculty - Gynecology Clinic
• Muenster Westfealische Wilhelms-Universitat
• Muenster Raphael Clinic - Emergency Department

Experience

• Liv Hospital Ulus
• Doğubeyazıt Dr. Yaşar Eryılmaz State Hospital
• Keşan Community Health Center

Research: 

• Kubra Karakolcu, Burak Bayraktar, Meric Balikoglu Leydig cell ovarian tumor in pregnancy: a case report. 1st International TRNC Gynecology and Obstetrics Congress
• Kubra Karakolcu, Ozge Cakir Nemli Management of a Fourth Degree Laceration After Vaginal Delivery.  4th ECIC: European Congress on Intrapartum Care
• Kubra Karakolcu, Halil Gursoy Pala, Deniz Tas Comparison of Bishop Score and Intrapartum Ultrasound Score in Prediction of Birth Results. 14th TAJEV Congress
• Oral presentation on Intrapartum Ultrasonography. 20th National Gynecology and Obstetrics Congress-TJOD 2023
• Oral presentation on Oocyte and Embryo freezing. 2nd National In Vitro Fertilization and Infertility Association Congress-TUBİD 2023

Publications: 

• Kayapinar A, Çetin D, Pakoz Z, KARAKOLCU K, Ertas I, Kamer E (2022). Short and long term results of anatomical reconstruction of perineal body and sphincter complex in obstetric anal sphincter injuries. Turkish Journal of Surgery, 38(2), 159 - 168. 10.47717/turkjsurg.2022.5528

Dermatologist

Dr. Ercan Ozden is a specialist in internal medicine and medical oncology. He earned his medical degree and completed his residency at Istanbul University, Cerrahpaşa Faculty of Medicine. He later received a subspecialty in medical oncology at Kocaeli University Faculty of Medicine from 2016 to 2020.

Dr. Ozden has worked in medical oncology at Şırnak State Hospital. He has also served as an internal medicine specialist at Bağcılar Private Safa Hospital and Küçükçekmece Batı Bahat Hospital. He has extensive clinical experience in both internal medicine and oncology.

Professeur agrégé Dr Yusuf AÇIKGÖZ
Spécialisation : Oncologie médicale

Éducation:

• 2004-2011 : Faculté de médecine de l'Université d'Inönü
• 2011-2016 : Hôpital de formation et de recherche Numune d'Ankara, médecine interne
• 2017-2022 : Université des Sciences de la Santé, Oncologie Médicale

Expérience professionnelle :

• 2016-2017 : Hôpital municipal de Bingöl, médecine interne
• 2021-2022 : Université des Sciences de la Santé, Oncologie Médicale
• 2022-2023 : Hôpital d'enseignement et de recherche de Kastamonu, oncologie médicale
• 2023-2024 : Université d'État de l'Ohio, oncologie médicale
• 2024-présent : Université Lokman Hekim, Oncologie médicale, Hôpital d'Ankara

Essais cliniques, cours, certifications :

Essais cliniques :

• 2017-2021 : Phase III, étude CheckMate-649 (chercheur adjoint)
• 2022-présent : Phase III, étude Fortitude-101 (chercheur adjoint)

Cours :

• 2018 : Programme de formation de base et avancée en biostatistique Medicres (en cours), Istanbul-Vienne
• 2019 : Cours de formation en immuno-oncologie, 1er et 2 mars 2019, Vienne, Central European Cooperative Oncology Group (CECOG)
• 2018 : Certification de bonnes pratiques cliniques, 7-8 avril 2018, Ankara, Université des sciences de la santé
• 2017 : Programme de formation de base en oncologie, 25-26 novembre 2017, Adana, Clinical Oncology Society
• 2016 : Cours de base en échographie (10 heures théoriques + 10 heures pratiques), 24-25 septembre 2016, Ankara, Association turque de médecine d'urgence

Certifications:

• En cours : Certification ECFMG
• 2024 : Conduite responsable de la recherche du CITI (Université d'État de l'Ohio)
• 2024 : CITI IACUC-Recherche sur les animaux de laboratoire (Université d'État de l'Ohio)
• 2024 : CITI Human Subjects Protection (Université d'État de l'Ohio)
• 2024 : Bonnes pratiques cliniques du CITI (Université d'État de l'Ohio)
• 2023 : Test d'anglais professionnel (OET)
• 2019 : International English Language Testing System (IELTS), score total : 6,5, 26 mai 2019, Ankara, British Council
• 2017 : examen USMLE Step 2 CK ; score : 244, 7 février 2017
• 2016 : examen USMLE Step 1 ; score : 215, 25 août 2016

Adhésions :

• Société américaine d'oncologie clinique (ASCO) - 2022
• Société turque d'oncologie médicale - 2020

Areas of Interests

• Breast cancer
• Lung cancer
• Colorectal cancers
• Gynecological and urogenital cancers
• Molecular Oncology

Education:

• Kızıltepe Anatolian High School 2001
• Dicle University Faculty of Medicine 2007
• Istanbul Medeniyet University Göztepe Training and Research Hospital 2014
• Kartal City Hospital 2021
• Associate Professor of Medical Oncology 2023

Experience:

• Liv Hospital Ulus
• Adıyaman University Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital
• Istanbul Umraniye Training and Research Hospital

Research:

• Phase II, Randomized, Open-Label, Multicenter Study to Comparatively Evaluate the Efficacy and Safety of GDC-9545 and Physician-Preferred Endocrine Monotherapy in Previously Treated, Estrogen Receptor Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer Patients, Other ( International), Dr. Murat Ayhan
• Phase III, Randomized, Evaluating the Efficacy and Safety of Palbociclib and Fulvestrant with Gdc-0077 Compared with Placebo in Patients with Pik3ca-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer. Double Blind, Placebo Controlled Study, Other (International), Dr. Murat Ayhan
• Randomized, Multicenter, Phase Ib/III Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Atezolizumab Compared to Intravenous Atezolizumab in Patients with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer, Other (International) Dr. Murat Ayhan
• Randomized, Controlled, Multicenter, Open-Label Study Including Observation Follow-Up for PSMA-PET-Negative Patients, Investigating the Efficacy and Safety of Addition of Apalutamide to Radiotherapy and LHRH Agonist in PSMA-PET-Positive High-Risk Hormone-Sensitive Prostate Cancer Patients, Other (International) Dr. Murat Ayhan
• Biomarker Study to Identify Patients with Advanced Stage Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations-42756493BLC0002, Other (International), Dr. Murat Ayhan
• Publications:
• Ayhan M, Turan N, Köstek O, et all. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology? Curr Probl Cancer. 2021 Jun;45(3):100670. doi: 10.1016/j.currproblcancer.2020.100670.
• Ayhan M, Odabas H, Turan N, et all. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience. J Chemother. 2021 Nov;33(7):499-508. doi: 10.1080/1120009X.2021.1923153.
• Ayhan M, Laçin Ş, Özyükseler DT, et all. Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer? J Oncol Pharm Pract. 2021 Sep;27(6):1461-1467. doi: 10.1177/10781552211015762.
• Ayhan M, Abamor E, Coban Kokten S, et al. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer. EJMI 2022;6(2):165–175.
• Ayhan M, Terzioglu K. Experience With Rapid Drug Desensitization With Chemotherapeutics; A SingleCentre Retrospective Study. EJMI 2021;5(3):380–387.
• Doğan A, AYHAN M. Survival analysis of patients with triple-negative breast cancer: a single-center experience. Journal of Oncological Sciences, 8(2), 94-99., Doi: 10.37047/jos.2022-89749
• Terzioğlu K, Ayhan M. Comparative Assessment of Platinum Salts and Taxane Group Hypersensitivity Reactions, The Role of Skin Tests in Diagnosis? J Oncol Pharm Pract. 2021 Nov 30:10781552211050084. doi: 10.1177/10781552211050084.
• Tacar SY, Selcukbiricik F, Yilmaz M, Erturk K, Murat Sarici A, Gulturk I, Ayhan M, Tural D. Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study. Melanoma Res. 2021 Oct 1;31(5):449-455. doi: 10.1097/CMR.0000000000000744.
• Özyurt E, Özçelik S, Sürmeli H, Çelik M, Ayhan M, Özçelik M. Side effects of immune-checkpoint inhibitors: Can multiple side effects be seen in a patient? J Oncol Pharm Pract. 2022 Mar;28(2):462-465. doi: 10.1177/10781552211038136.
• Dülgar Ö, Öven BB, Atcı MM, Arıkan R, Ay S, Ayhan M, Selvi O, Ozyukseler DT, Bayram E, Özcan E, Yasin Aİ, Gümüş M. Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Rev Anticancer Ther. 2022 Jul;22(7):773-780. doi: 10.1080/14737140.2022.2076670.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. J Cancer Res Clin Oncol. 2022 Jun;148(6):1501-1508. doi: 10.1007/s00432-021-03748-7.
• Volume I, Kucukarda A, Atcı MM, Ayhan M, et all. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study. Tumori. 2022 Feb;108(1):19-25. doi: 10.1177/03008916211037739.
• Dogan I, Ayhan M, Gurbuz M, et all. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022 Sep 2;101(35):e30147. doi: 10.1097/MD.0000000000030147.
• Ozcelik M, Oyman A, Cil I, Duzgun O, Ozkan OF, Ayhan M. Cytoreductive Surgery versus Systemic Chemotherapy alone in Isolated Peritoneal Carcinomatosis of Colorectal Origin. J Coll Physicians Surg Pak. 2021 Nov;31(11):1308-1313. doi: 10.29271/jcpsp.2021.11.1308.
• Başoğlu T, Sakin A, Erol C, Ayhan M, et all. Real life experienceof patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. J Chemother. 2022 May 17:1-8. doi: 10.1080/1120009X.2022.2073159.
• Özdemir Ö, Zengel B, Yildiz Y, Ayhan M, et all. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study. Anticancer Drugs. 2022 Aug 1;33(7):663-670. doi: 10.1097/CAD.0000000000001310.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study). J Cancer Res Clin Oncol. 2022 Sep 1. doi: 10.1007/s00432-022-04252-2.
• Hizal M, Bilgin B, Paksoy N, Ayhan M, et all. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study. Future Oncol. 2022 Jul;18(23):2573-2582. doi: 10.2217/fon-2022-0083.
• Topcu A, Atci MM, Secmeler S, Besiroglu M, Ayhan M, Ozkan M, Bozkurt O, Urakci Z, Ay S, Geredeli C, Yasin AI, Turk HM. Efficacy of trastuzumab and potential risk factors on survival in patients with HER2-positive metastatic gastric cancer. Future Oncol. 2021 Nov;17(31):4157-4169. doi: 10.2217/fon-2021-0398.
• Bilgin B, Sendur MAN, Yucel S, Ayhan M, et all. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study. J Cancer Res Clin Oncol. 2021 Jul;147(7):2145-2152. doi: 10.1007/s00432-020-03501-6.
• Atci MM, Akagunduz B, Demir M, Arikan R, Ay S, Ozer M, Ayhan M, Cil I, Demir N, Ozyurt N, Karakaya G, Cevik GT, Onder AH, Selvi O, Sakin A. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. J Chemother. 2023 Feb;35(1):19-28. doi: 10.1080/1120009X.2022.2040770.
• Tataroglu Ozyukseler D, Ay S, Turan M, Alkan G, Ayhan M, Surmeli H, et al. The Systemic Inflammation Response Index as a Prognostic Marker in Advanced Pancreatic Cancer. EJMI 2022;6(3):367–373.
• Yıldız F, Ayhan M, Demir H, et all. Comparing the efficacy of cabazitaxel in secondline and third-Line treatment of metastatic castration-resistant prostate cancer: a multi-center experience from Turkey. International Journal of Contemporary Medical Research, 7(9), 112-116.,Doi: 10.21276/ijcmr.2020.7.9.30
• Terzioğlu K, Ayhan M. Distribution of allergens detected on patch tests of patients with allergic contact dermatitis and investigation of their atopic background. Annals of Medical Research, 29(5), 422-426., doi: 10.5455/annalsmedres.2021.07.490
• Arikan R, Atci MM, Ay S, Ayhan M, et all Prognostic significance of mucinous histology in left sided metastatic colorectal cancers with wild type RAS and evaluation of backbone chemotherapy regimens. Oncol Lett. 2023 Apr 5;25(5):208. doi: 10.3892/ol.2023.13795.
• Almuradova E, Yalcin S, Arıkan R, Ayhan M, Demir H, Cevik GT, Karaca M, Petekkaya I, Karabulut B. Survival of Patients With Metastatic Rectum Cancer Who Underwent Metastasectomy Following Conversion Chemotherapy Sans Pelvic Radiotherapy: A Turkish Oncology Group Study. Cureus 2023 May 17;15(5):e39119. doi: 10.7759/cureus.39119.
• Topcu A, Besiroglu M, Atci MM, Ayhan M, et all. Second-line Therapy after Trastuzumab Failure in HER2-Positive Metastatic Gastric Cancer: A Real-life Data. EJMI 2023;7(2):153–161. DOI: 10.14744/ejmi.2023.22720
• Book Writing:
• Drug interactions and side effects of targeted agents, Section name: (Small molecule tyrosine kinase inhibitors; ROS-1 targeted therapies (Crizotinib, Seritinib)) (2021)., AYHAN MURAT, Turkish Clinics Journal of Medical Sciences, Editor: Mehmet Aliustaoglu, Publishing number:1, Number of Pages 92, ISBN:978-625-401- 466-6, Turkish
• Approach to gastrointestinal stromal tumors and neuroendocrine tumors, Department name: (Medical approach in primary non-gastrointestinal neuroendocrine tumors) (2020)., AYHAN MURAT, Akademisyen Yayınevi, Editor: Anılır Ender, Number of editions: 1, Number of Pages 382, ISBN: 9786052585719, Turkish
• Internal medicine emergencies, Department name: (Oncological emergencies) (2022)., YILDIRIM SEDAT, AYHAN MURAT, Efe Academic Publishing, Editor: Serdar Olt, Number of editions: 1, Number of Pages 232, ISBN: 978-625-8324-66- 2, Turkish
• Physicians' chemotherapy cancer drug manual 2020, Section name: (Common chemotherapy regimens in clinical practice) (2022)., SÜMBÜL AHMET TANER, ALKAN ALI, AKSOY ASUDE, AYHAN MURAT, et all, Türkiye Klinikleri Journal of Medical Sciences, Editor: EDWAR CHU, VINCENT T. DEVITA, SAADDETIN KILIÇKAP, CEMIL BILIR, SELÇUK SEBER, Number of editions: 1, Number of pages 772, ISBN: 978-625-401-290- 7, Turkish (Book Translation)

Areas of Interests

• Infertility
• In Vitro Fertilization (IVF) Treatment
• Endometriosis
• Urogynecology (urinary incontinence and uterine prolapse surgeries)
• Gynecological Laparoscopic surgeries
• Hysteroscopic surgeries
• Pregnancy Monitoring
• Myoma surgery
• Ovarian cysts and surgeries
• Gynecological plastic surgeries

Education:

• Ataturk University Faculty of Medicine - Undergraduate
• Abant Izzet Baysal University Faculty of Medicine Gynecology and Obstetrics - Specialization
• Bezmialem Vakif University Faculty of Medicine Istanbul - Assistant Professorship
• Bezmialem Vakif University Faculty of Medicine Istanbul - Associate Professorship
• American Hospital - Assisted Reproductive Specialist Training

Experience:

• Bolu Izzet Baysal State Hospital (Compulsory Service) -Bolu
• Bezmialem Vakif University Faculty of Medicine - Istanbul

Areas of Interests

• High Risk Pregnancies
• Perinatology
• Detailed Fetal Ultrasound
• High Risk and Complicated Births

Education

• Mudanya Ahmet Rushdie High School
• Ege University Faculty of Medicine
• Istanbul University, Istanbul Faculty of Medicine, Department of Obstetrics and Gynecology
   

Experience

• Gümüşhacıköy State Hospital, Gynecology and Obstetrics Clinic (State compulsory service obligation)
• Kasımpaşa Naval Hospital, Gynecology and Obstetrics Clinic (Military service)
• Erciyes University, Faculty of Medicine, Department of Obstetrics and Gynecology, Perinatology and High Risk Pregnancies Unit
• Bezmialem Vakif University, Faculty of Medicine, Department of Obstetrics and Gynecology, Prenatal Diagnosis and High Risk Pregnancies Unit
• Haukeland University Hospital, Obstetrics and Gynecology, Fetal Physiology Unit, March- 2020, Bergen/Norway
• Haukeland University Hospital, Obstetrics and Gynecology, Advanced operative vaginal delivery, May, 2022, Bergen/Norway

Dr. Baha Zengel is a general surgeon with expertise in breast, gallbladder, thyroid diseases, and hernia repairs. He graduated from Ege University Faculty of Medicine in 1990. In 2004, he earned a doctorate in Basic Oncology from Dokuz Eylül University. He became an Associate Professor of General Surgery in 2014 through the Inter-University Board.

Dr. Zengel is skilled in advanced surgical procedures. His experience includes skin and breast-conserving mastectomy, oncoplastic breast surgery, laparoscopic cholecystectomy, sentinel lymph node biopsy, and ROLL/SNOLL techniques. He has held important positions at Izmir Bozyaka Training and Research Hospital, including Education Officer.

He is a member of several professional associations. He serves on the Board of Directors of the Aegean Region Surgery Association and is a founding board member of the Basic Oncology Association.

Urologue, Oncochirurgien

Spécialisations

Chirurgie du cancer

Chirurgie du pancréas

Chirurgie des voies biliaires

Chirurgie métabolique bariatrique

Chirurgie oncologique

Chirurgie mammaire

Cancer gastrique

Cancer du côlon

Cancer de la thyroïde

Chirurgie de l'obésité

Chirurgies pour le diabète